Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

20051,850 citationsJournal Article

Authors

Ming‐Sound Tsao · University of Toronto

Akira Sakurada · Ontario Institute for Cancer Research

Jean-Claude Cutz · Ontario Institute for Cancer Research

Chang‐Qi Zhu · Cancer Institute (WIA)

Suzanne Kamel‐Reid · University of Toronto

Jeremy A. Squire · Ontario Institute for Cancer Research

Ian Lorimer

Abstract

Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.

Topics & Keywords

Lung Cancer Treatments and Mutations Peptidase Inhibition and Analysis Gastric Cancer Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 353, Issue 2, pp. 133-144

DOI: 10.1056/nejmoa050736

Field-Weighted Citation Impact: 162.30